Stabilization and multidose use of exametazime for cerebral perfusion studies

Nuclear Medicine Communications

Volumn 15, Issue 9, 1994, Pages 718-722

  Solanki, C ^a   Li, D J ^a   Wong, A ^a   Barber, R W ^a   Wraight, E P ^a   Sampson, C B ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; UNCLASSIFIED DRUG;

ARTICLE; BRAIN BLOOD FLOW; BRAIN SCINTISCANNING; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

COMPARATIVE STUDY; DRUG STABILITY; HUMAN; ORGANOTECHNETIUM COMPOUNDS; OXIMES; PROBABILITY; SOLUTIONS; TECHNETIUM TC 99M EXAMETAZIME; TIME FACTORS; TIN FLUORIDES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0028024744     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-199409000-00009     Document Type: Article

References (20)

1. Ell PJ, Hocknell JML, Jarritt PH et al. A 99Tcm-labelled radiotracer for the investigation of cerebral vascular disease. Nucl Med Commun 1985; 6: 437-41.
2. Yeh SH, Liu RS, Hu HH et al. Brain SPECT imaging with 99Tcm-hexamethylpropyleneamine oxime in the early detection of cerebral infarction. Comparison with transmission computed tomography. Nucl Med Commun 1986; 7: 873-8.
3. Neirinckx RD, Canning LR, Piper IM et al. Technetium- 99m d-1 HMPAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion J Nucl Med 1987; 28: 191-202.
4. Perani D, DiPiero V, Vallar G et al. Technetium-99m HMPAO-SPECT study of regional cerebral perfusion in early Alzheimer's disease.J Nucl Med 1988; 29: 1507-14.
5. Smith F, Besson JA, Gemmell HG et al. The use of technetium 99mTc HMPAO in assessment of patients with dementia and other neuropsychiatric conditions. Cereb Blood Flow Metab 1988; 8: S116-22.
6. Ryding E, Rosea I, Elmqvist D et al. SPECT measurements with 99mTc-HMPAO in focal epilepsy.J Cereb Blood Flow Metab 1988; 8: S95-100.
7. Laurin NR, Driedger AA, Hurwitz GA et al. Cerebral perfusion imaging with technetium-99m HM-PAO in brain death and severe central nervous system injury.J Nucl Med 1989; 30: 1627-35.
8. Reid RH, Gulenchyn KY, Ballinger JR. Clinical use of technetium-99m HM-PAO for determination of brain death. J Nucl Med 1989; 30: 1621-6.
9. Neirinckx RD, Harrison RC, Forster AM et al. A model for the in vivo behaviour of Tc-99m d,l- HMPAO in man. 1 Nucl Med 1987; 28: 559.
10. Hung JC, Corlija M, Volkert WA et al. Kinetic analysis of technetium-99m d,l-HM-PAO decomposition in aqueous media. J Nucl Med 1988; 29: 1568-76.
11. Amersham International pic. Ceretec package insert.
12. Hung JC, Volkert WA, Holmens RA. Stabilization of Tc- 99m dl HMPAO using gentisic acid. Nucl Med Biol 1989; 16: 675-80.
13. Lang J, Barbarics E, Lazar J et al. Effects of labelling conditions and formulations of kit on in vitro stability of Tc-99m D,L HMPAO. Eur J Nucl Med 1989; 15: 424.
14. Billinghurst MW, Abrams DN, Lawson MS. Stabilization of 99mTc HMPAO-1. Ethanolic preparation. Int J Appl Radiat Isotop 1991; 42: 607-12.
15. Ballinger JR, Gulenchyn KY. Alternative formulations of technetium-99m HMPAO. Int J Appl Radiat Isotop 1991; 42: 315-16.
16. Sampson CB, Solanki C. Stabilization of Tc-99m exametazime using ethanol and storage at low temperature. Eur Nucl Med 1991; 18: 532.
17. Weisner PS, Bower GR, Dollimore LA et al. A method for stabilising technetium-99m exametazime prepared from a commercial kit. Eur J Nucl Med 1993; 20: 661-6.
18. Solanki C, Li DJ, Wong A, Miles K, Sampson CB. Multidose use of exametazime for leucocyte labelling: a new approach using tin enhancement. Nucl Med Commun 1993; 14: 1035-40.
19. Ballinger J. Preparation of Tc-99m HMPAO. J Nucl Med 1990; 31: 1892.
20. Hawkins T, Reeder A, Keavey PM et al. The long term stability of reconstituted exametazine: a clinical and laboratory evaluation. Nucl Med Commun 1991; 12: 1045-55.